CORE
COnnecting
REpositories

    5 research outputs found

    Positive Behavior Intervention Support Handbook for Paraeducators

    Author
    Publication venue
    Publication date
    Field of study
    No full text
    Challenging behaviors in the classroom can be taxing on everyone in the classroom. When behavioral needs are not met, academics can decline. Maintaining a safe and ready to learn environment requires meeting behavioral needs of all students, from minor behavior disruptions such as side talk and being out of seat to major disruptions such as yelling, refusal of work, and any unsafe behaviors. These challenging behaviors can happen in special and general education classrooms and the staff members who have a front row seat to these behaviors are paraeducators. Paraeducators are staples in the classroom, supporting students academically and behaviorally and they may often have limited resources to manage these behaviors. In order to provide paraeducators with more resources, the author aligned Positive Behavior Intervention Support (PBIS) and Win-Win Discipline (Kagan, Kyle, & Scott, 2004) in order to create a handbook for paraeducators focusing on how to best support students with challenging behaviors. The handbook provides an overview of PBIS, brief description of each Tier of the Multi-Tiered System of Support (MTSS), supports used in each Tier, and worksheets that paraeducators can use throughout the day. The author’s goal is to provide paraeducators with more support and resources in supporting students with challenging behaviors in the classroom and throughout their daily interactions
    ScholarWorks (California State University)

    Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma

    Author
    Publication venue
    Publication date
    Field of study
    No full text
    BACKGROUND: Cutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the oncolytic virus talimogene laherparepvec improved durable response rate (DRR; continuous response ≥6 months) compared with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). METHODS: Retrospective review of OPTiM identified patients with cutaneous head and neck melanoma given talimogene laherparepvec (n = 61) or GM-CSF (n = 26). Outcomes were compared between talimogene laherparepvec and GM-CSF treated patients with cutaneous head and neck melanoma. RESULTS: DRR was higher for talimogene laherparepvec-treated patients than for GM-CSF treated patients (36.1% vs 3.8%; p = .001). A total of 29.5% of patients had a complete response with talimogene laherparepvec versus 0% with GM-CSF. Among talimogene laherparepvec-treated patients with a response, the probability of still being in response after 12 months was 73%. Median overall survival (OS) was 25.2 months for GM-CSF and had not been reached with talimogene laherparepvec. CONCLUSION: Treatment with talimogene laherparepvec was associated with improved response and survival compared with GM-CSF in patients with cutaneous head and neck melanoma. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1752-1758, 2016
    Crossref
    Carolina Digital Repository
    Institute of Cancer Research Repository

    Real-world outcomes with immuno-oncology therapies in advanced melanoma: Final results of the OPTIMIzE registry study

    Author
    Publication venue
    Publication date
    Field of study
    No full text
    Aim: The OPTIMIzE registry study evaluated real-world outcomes in patients with advanced melanoma receiving immuno-oncology therapies. Materials and methods: Data were collected for patients treated with anti-programmed death 1 (PD-1) monotherapy (nivolumab or pembrolizumab; n = 147) or nivolumab plus ipilimumab (n = 81) from 2015-2017 and followed for ≥3 years. Results: Nivolumab plus ipilimumab versus anti-PD-1 monotherapy was associated with a nonsignificantly lower risk of death (adjusted HR: 0.83; 95% CI: 0.54-1.28; p = 0.41), higher disease control rate (72 vs 56%; p = 0.04), and stable quality of life, but more grade 3-4 treatment-related adverse events (54 vs 26%; p \u3c 0.0001). Conclusion: These results support the use of immuno-oncology therapy in advanced melanoma
    SHARE @ Advocate Health - Midwest
    Aurora Health Care Digital Repository

    31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

    Author
    Publication venue
    Publication date
    Field of study
    No full text
    For a complete list of authors, please look at article.http://deepblue.lib.umich.edu/bitstream/2027.42/134674/1/40425_2016_Article_173.pd
    Crossref
    Springer - Publisher Connector
    Archivio della Ricerca - Università di Pisa
    University of Miami: Scholarship@Miami
    Helsingin yliopiston digitaalinen arkisto
    Deep Blue Documents

    Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19

    Author
    Publication venue
    Publication date
    Field of study
    No full text
    Crossref
    UNIL IRIS | Institutional Research Information System
    corecore